Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | AKT1 | P31749 | 2/20 | 0.69 |
| ▸ | ESR1 | P03372 | 1/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.69 |
| ▸ | CDC25A | P30304 | 1/20 | 0.69 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.69 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.62 |
| ▸ | PRKCG | P05129 | 1/20 | 0.62 |
| ▸ | PRKCB | P05771 | 1/20 | 0.62 |
| ▸ | PRKCA | P17252 | 1/20 | 0.62 |
| ▸ | PRKCH | P24723 | 1/20 | 0.62 |
| ▸ | PRKCI | P41743 | 1/20 | 0.62 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.62 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.62 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1850083 | 1.00 | LMNA (0.69) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL30008220 | 1.00 | LMNA (0.69) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL10938318 | 1.00 | LMNA (0.69) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL10937575 | 1.00 | LMNA (0.69) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL10934199 | 1.00 | LMNA (0.69) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL23016704 | 0.92 | LMNA (0.82) | LMNAAKT1ESR1ADORA3CDC25A | |
| Elaidylphosphocholine SCHEMBL18952927 | 0.92 | LMNA (0.82) | LMNAAKT1ESR1ADORA3CDC25A | |
| Elaidylphosphocholine SCHEMBL10415339 | 0.92 | LMNA (0.82) | LMNAAKT1ESR1ADORA3CDC25A | |
| Oleylphosphocholine SCHEMBL3332097 | 0.92 | LMNA (0.82) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL23016878 | 0.92 | LMNA (0.82) | LMNAAKT1ESR1ADORA3CDC25A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4619025-A1 | COMPOSITIONS AND METHODS FOR CHARACTERIZING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH MULTIPLE ORGAN FAILURE | Arizona Board of Regents on behalf of The University of Arizona (US) | 2025-09-24 | — | — | EP | claimed |
| WO-2024107800-A1 | COMPOSITIONS AND METHODS FOR CHARACTERIZING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH MULTIPLE ORGAN FAILURE | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-05-23 | — | — | WO | claimed |
| US-20240052352-A1 | COMPOSITIONS AND METHODS FOR CHARACTERIZING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH MULTIPLE ORGAN FAILURE | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2024-02-15 | — | — | US | claimed |
| WO-2022178407-A1 | COMPOSITIONS AND METHODS FOR CHARACTERIZING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH MULTIPLE ORGAN FAILURE | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2022-08-25 | — | — | WO | claimed |
| US-20210236500-A1 | INHIBITION OF AUTOPHAGY USING PHOSPHOLIPASE A2 INHIBITORS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2021-08-05 | — | — | US | claimed |
| US-20190142835-A1 | INHIBITION OF AUTOPHAGY USING PHOSPHOLIPASE A2 INHIBITORS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2019-05-16 | — | — | US | claimed |
| US-20010026927-A1 | Measuring method and measuring reagent of C-reactive protein | KYOWA MEDEX CO., LTD. (JP) | 2001-10-04 | — | — | US | claimed |
| EP-1130396-A1 | Measuring method and measuring reagent of C-reactive protein | KYOWA MEDEX CO., LTD. (JP) | 2001-09-05 | — | — | EP | claimed |
| US-6099834-A | Method for modulating eicosanoid mediated immune responses in arthropods | BOARD OF REGENTS UNIVERSITY OF NEBRASKA-LINCOLN (US) | 2000-08-08 | — | — | US | claimed |
| EP-4619025-A1 | COMPOSITIONS AND METHODS FOR CHARACTERIZING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH MULTIPLE ORGAN FAILURE | Arizona Board of Regents on behalf of The University of Arizona (US) | 2025-09-24 | — | — | EP | disclosed |
| WO-2024107800-A1 | COMPOSITIONS AND METHODS FOR CHARACTERIZING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH MULTIPLE ORGAN FAILURE | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20240052352-A1 | COMPOSITIONS AND METHODS FOR CHARACTERIZING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH MULTIPLE ORGAN FAILURE | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2024-02-15 | — | — | US | disclosed |
| US-20220062379-A1 | METHODS AND COMPOSITIONS FOR MODULATING IMMUNE DYSREGULATION | VALORISATION HSJ, LIMITED PARTNERSHIP (CA) | 2022-03-03 | — | — | US | disclosed |
| US-20210236500-A1 | INHIBITION OF AUTOPHAGY USING PHOSPHOLIPASE A2 INHIBITORS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2021-08-05 | — | — | US | disclosed |
| WO-2002000924-A2 | VIRAL PHOSPHOLIPASE A2 ENZYMES, ANTI-VIRAL AGENTS AND METHODS OF USE | INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) | 2002-01-03 | — | — | WO | disclosed |
| US-20010026927-A1 | Measuring method and measuring reagent of C-reactive protein | KYOWA MEDEX CO., LTD. (JP) | 2001-10-04 | — | — | US | disclosed |
| EP-1130396-A1 | Measuring method and measuring reagent of C-reactive protein | KYOWA MEDEX CO., LTD. (JP) | 2001-09-05 | — | — | EP | disclosed |
| US-4542219-A | ANTITUMOR, AGRICULTURAL FUNGICIDES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1985-09-17 | — | — | US | disclosed |
| EP-0061872-B1 | ETHYLENEGLYCOL DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1985-08-07 | — | — | EP | disclosed |
| EP-0061872-A1 | Ethyleneglycol derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1982-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010026927-A1 | Measuring method and measuring reagent of C-reactive protein | PON1, ARG1, PHOSPHO1 | LMNA 574/4885AKT1 2277/4885ESR1 4467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.